Bondrova 3 mg/3 ml (IV Infusion)
3 ml vial: ৳ 4,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
Pharmacology
- Inhibition of bone resorption
- Prevention of experimentally induced bone destruction
- Highly potent inhibitor of osteoclastic activity
- Increase in bone mass
- Selective action on bone tissue
- Reduction of bone resorption
- No direct effect on bone formation
Dosage & Administration
- Recommended dose of one 150 mg film-coated tablet once a month
- Tablet should be taken 60 minutes before the first food of the day
- Swallowed whole with plain water
- Supplemental calcium or vitamin D if dietary intake is inadequate
- Instructions for missed doses
Interaction
- Potential interference with calcium supplements, antacids, and some oral medications
- No interaction potential with tamoxifen or hormone replacement therapy
- Absence of interaction with melphalan/prednisolone
- Increased bioavailability when co-administered with i.v. ranitidine
Contraindications
- Known hypersensitivity to ibandronic acid or its excipients
- Uncorrected hypocalcemia
- Abnormalities of the esophagus delaying esophageal emptying
- Inability to stand or sit upright for at least 60 minutes
Side Effects
- Dyspepsia
- Nausea
- Diarrhea
- Abdominal pain
- Muscle aches
- Headaches
- Dizziness
Pregnancy & Lactation
- Not to be used during pregnancy
- No evidence for direct fetal toxic or teratogenic effects in animal studies
- Not to be used during lactation
Precautions & Warnings
- Treatment of hypocalcemia and other bone/metabolism disturbances before therapy
- Caution in active upper gastrointestinal problems
- Risk of esophageal adverse experiences
- Caution in concomitant medication with NSAIDs
- Risk of osteonecrosis of the jaw
- Caution in patients requiring dental procedures
Use in Special Populations
- No dosage adjustment for mild or moderate renal impairment
- Individual risk-benefit assessment for creatinine clearance below 30 ml/min
- No dosage adjustment for hepatic impairment
- No dosage adjustment for elderly patients
- Safety and efficacy not established in patients less than 18 years old
Overdose Effects
- Upper gastrointestinal adverse events
- Use of milk or antacids to bind Bondrova
- Avoid inducing vomiting
Therapeutic Class
Bisphosphonate preparations
Storage Conditions
Keep below 30°C temperature, away from light & moisture, and out of the reach of children